Efficacy and Safety of LY01011 and Xgeva® in Patients With Bone Metastases From Solid Tumors

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
This is a multicenter,randomized, double-blind, active-controlled, parallel-group study comparing efficacy and safety of LY01011 (recombinant anti-RANKL human monoclonal antibody injection) and Xgeva® in patients with bone metastases from solid tumors.
Epistemonikos ID: d2ec92c7301a5f31e2de18c5f3b5fd0fe5781b34
First added on: May 08, 2024